1 The effects of tienoxolol, (ethyl 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-5-[(2-thienylcarbonyl) amino] benzoate, hydrochloride), a novel drug exhibiting both diuretic and Padrenoceptor blocking properties, were investigated on urinary 6-keto-prostaglandin Fl, (6-keto-PGFI,) and PGE2 excretion in the rat and compared to those of reference diuretic (furosemide) and Padrenoceptor antagonists (acebutolol, propranolol). Since tienoxolol was shown to bind to A, and A2 adenosine receptors, the action of theophylline was also evaluated.2 Tienoxolol (8-128mgkg-', p.o.) induced a dose-related increase of 6-keto-PGFI, excretion from 32 mg kg-' but a significant elevation of urinary PGE2 levels was only reached after administration of 128 mg kg-'. However, renal prostaglandin concentrations were not modified by tienoxolol.3 Furosemide (32 mg kg-') displayed a strong diuretic activity but did not enhance 6-keto-PGFI,, excretion. Likewise, the latter was unaffected by acebutolol and propranolol (128 mg kg-') and no significant diuresis was observed following administration of these two P-blocking agents. Theophylline (64 mg kg-1), like tienoxolol, was able to induce both diuresis and urinary prostaglandin excretion. Furthermore, they bound with similar affinities to A, and A2 adenosine receptors. This led to the suggestion that a relationship between P,-purinoceptors, prostaglandin release, diuresis and natriuresis could exist.4 Oral co-administration of NECA (0.2 mg kg-') with tienoxolol markedly reduced the urinary 6-keto-PGF,c, excretion observed when tienoxolol was administered alone. However, neither diuresis nor natriuresis were modified, demonstrating that the proposed relationship was untenable. 5 In conclusion, PGI2 probably does not participate in the diuretic and natriuretic activity of tienoxolol. The increase of urinary 6-keto-PGF,g excretion may result not only from the haemodynamic properties of the drug but also from the rise of the urinary flow induced by tienoxolol.